Conventional manufacturing of dosage forms for small molecule drugs in centralized facilities is not well-suited to meet the needs of adaptive clinical trials for early-phase dose escalation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback